Catalyst Biosciences (CBIO) Announces Strong Preclinical Data on CB 2679d/ISU304 in Hemophilia B
Tweet Send to a Friend
Catalyst Biosciences, Inc. (Nasdaq: CBIO) announced positive results from a preclinical study of CB 2679d/ISU304 in well-validated models of hemophilia ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
